Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Evaluate Toxicogenomics Data for FDA

NEW YORK, Aug. 19 (GenomeWeb News) - Gene Logic has entered into an agreement with the US Food and Drug Administration's Center for Drug Evaluation and Research to use its gene expression data from control and treated rats to evaluate toxicogenomics data, the company said today.


The agreement is designed to assist the FDA in assessing quality of genomics data that is part of new drug submissions. The company said the results of the research will be publicly available.


"We are excited about working closely with Gene Logic scientists in the pursuit of our shared vision of evaluating standards which may become critical for future regulatory submissions," Karol Thompson, who will be the primary CDER investigator on this project, said in a statement. "In building on this agreement, we look forward to additional joint research efforts with Gene Logic aimed at increasing the safety and efficacy profile of drugs."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.